ArticleNutrition journal2025
Serum 25-hydroxyvitamin D levels and risk of overall and site-specific cancers in Korean adults: results from two prospective cohort studies.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Vitamin D deficiency modifies the association between ambient PMNutrition research and practice · 2026Article
- Hepatocellular carcinoma and vitamin D metabolism: novel targets and therapeutic strategies.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Vitamin D, Gut Microbiota, and Cancer Immunotherapy-A Potentially Effective Crosstalk.International journal of molecular sciences · 2025Review
- Correction: Serum 25-hydroxyvitamin D levels and risk of overall and site-specific cancers in Korean adults: results from two prospective cohort studies.Nutrition journal · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundThe link between vitamin D and cancer remains inconclusive. In this study, we aimed to explore the relationship between circulating vitamin D levels and overall and site-specific cancers in Korean adults using data from two large prospective cohort studies.
methodsBaseline serum 25-hydroxyvitamin D [25(OH)D] levels were measured in a subset of participants from the Cardiovascular Disease Association Study (2005-2012) and the Health Examinees Study (2009-2013). We followed 46,514 adults aged ≥ 40 years who consented to linkage with national cancer registry data. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer incidence according to quartiles of season-standardized 25(OH)D levels.
resultsThe median season-standardized 25(OH)D level was 45.6 nmol/L (interquartile range: 33.6-59.7 nmol/L). During the median follow-up of 10.6 years, 3,529 incident cancer cases were recorded. Compared with the first quartile, the upper quartiles of serum 25(OH)D were associated with a lower risk of overall cancer [HR (95% CI): 0.86 (0.77-0.95), 0.84 (0.75-0.93), and 0.80 (0.72-0.89), respectively; P for trend < 0.001]. For site-specific cancers, the HRs (95% CIs) for the comparison of extreme quartiles of serum 25(OH)D were 0.72 (0.52-0.99) for colorectal cancer, 0.32 (0.21-0.50) for liver cancer, and 0.75 (0.55-1.04) for lung cancer. Upon categorization of serum 25(OH)D levels based on absolute cut-off points, participants with levels ≥ 75 nmol/L had significantly lower risks of overall, liver, and lung cancers compared with those with levels < 30 nmol/L.
conclusionsThese findings suggest that higher 25(OH)D levels are associated with a lower risk of overall and some site-specific cancers in the Korean population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.